New Dual-Antibody drug takes aim at Hard-to-Treat cancers
NCT ID NCT07266428
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tumors or slow their growth. Participants receive OTP-01 by IV infusion and undergo regular blood tests and scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OTP-01 (a dual antibody targeting PD-1 and VEGFR2)
What this could lead to
If successful, this could lead to a new treatment option that shrinks tumors or slows their growth in people with advanced solid cancers.
What could go wrong
This is an early-phase trial with only 170 participants, so the drug may not work as hoped or could cause significant side effects. Results may not apply to all cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Auckland City Hospital
RECRUITINGAuckland, 1023, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cancer Research SA
RECRUITINGAdelaide, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chris O'Brien Lifehouse
RECRUITINGCamperdown, 2050, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fundación Jiménez Díaz
RECRUITINGMadrid, 28040, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital de Santa-Maria-Centro Hospitalar Lisboa Norte (CHLN)
RECRUITINGLisbon, 1649-036, Portugal
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Linear Clinical Research
RECRUITINGNedlands, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
START Dublin Early Phase Clinical Trials Unit
RECRUITINGDublin, D07 R2WY, Ireland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
South Texas Accelerated Research Therapeutics (START)
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
South Texas Accelerated Research Therapeutics (START) Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••